{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:41:58Z","timestamp":1782949318558,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2516.2010.02453.x","type":"journal-article","created":{"date-parts":[[2011,3,2]],"date-time":"2011-03-02T00:06:24Z","timestamp":1299024384000},"page":"439-445","source":"Crossref","is-referenced-by-count":12,"title":["An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact\u00ae), results of phase III and IV clinical studies"],"prefix":"10.1111","volume":"17","author":[{"given":"E. P.","family":"MAUSER-BUNSCHOTEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"KLEINE BUDDE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"LOPACIUK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M. W.","family":"KOOPMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J. M.","family":"Van Der MEER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. R. O.","family":"NOV\u00c0KOV\u00c0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"YPMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. W. G.","family":"Van Der LINDEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"WINDYGA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. F. W.","family":"STRENGERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1055\/s-0038-1653839","article-title":"Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity","volume":"73","author":"Gray","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1423-0410.2000.7820086.x","article-title":"Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products","volume":"78","author":"Foster","year":"2000","journal-title":"Vox Sang"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2516.2002.00617.x","article-title":"Factor VIII and transmissible spongiform encephalopathy: the case for safety","volume":"8","author":"Cervenakova","year":"2002","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.2001.0269","article-title":"Scrapie removal using Planova virus removal filters","volume":"29","author":"Tateishi","year":"2001","journal-title":"Biologicals"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB5|cit5","unstructured":"The European Agency for the Evaluation of Medicinal Products CPMP 198\/95, Final: \u2018Note for guidance to assess efficacy and safety of human plasma derived Factor VIII:C and Factor IX:C products in clinical trials in haemophiliacs before and after authorisation\u2019 1996"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB6|cit6","unstructured":"The European Agency for the Evaluation of Medicinal Products CPMP\/BPWG\/198\/95, rev. 1: \u2018Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products\u2019 2000"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood.V76.12.2540.2540","article-title":"Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate","volume":"76","author":"Mannucci","year":"1990","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2141.1991.tb08088.x","article-title":"No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate","volume":"79","author":"Mannucci","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-0038-1646288","article-title":"Multicentric evaluation of a new assay for prothrombin fragment F1\u2003+\u20032 determination","volume":"68","author":"Bruhn","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0038-1646423","article-title":"The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII\/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis","volume":"66","author":"Morfini","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1537-2995.1995.35495216081.x","article-title":"Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group","volume":"35","author":"Poon","year":"1995","journal-title":"Transfusion"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1537-2995.2002.00039.x","article-title":"Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B","volume":"42","author":"Ewenstein","year":"2002","journal-title":"Transfusion"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood.V98.13.3600","article-title":"Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates","volume":"98","author":"Roth","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2006-05-020495","article-title":"Cutaneous wound healing is impaired in hemophilia B","volume":"108","author":"Hoffman","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB15|cit15","first-page":"11","article-title":"Biochemical characterization of recombinant factor IX","volume":"35","author":"Bond","year":"1998","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2006.01401.x","article-title":"In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting","volume":"13","author":"Bjorkman","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB17|cit17","first-page":"33","article-title":"Clinical evaluation of recombinant factor IX","volume":"35","author":"White","year":"1998","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0038-1657536","article-title":"Recombinant factor IX","volume":"78","author":"White","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB19|cit19","first-page":"6","article-title":"Preclinical studies of a monoclonal antibody-purified factor IX, Mononine","volume":"28","author":"Hrinda","year":"1991","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1365-2516.2010.02453.x-BIB20|cit20","first-page":"1206","article-title":"Analytical characterization of recombinant human factor IX (rhFIX)","volume":"73","author":"Rodrigues","year":"1995","journal-title":"Thromb Haemost"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2010.02453.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2516.2010.02453.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T09:59:02Z","timestamp":1625392742000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2010.02453.x"}},"subtitle":["PHASE III\/IV STUDIES WITH PLASMA FIX (NONAFACT\u00ae)"],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02453.x","relation":{},"ISSN":["1351-8216"],"issn-type":[{"value":"1351-8216","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}